Zolbetuximab: An Investigational First-Line Treatment for CLDN18.2-positive, HER2-negative Gastric and Gastro-oesophageal Junction Cancer.
| Autor: | Al Karmi, Joud1 joudkarmi99@gmail.com, Gibson, Michael K.2,3 |
|---|---|
| Zdroj: | touchREVIEWS in Oncology & Haematology. 2023, Vol. 19 Issue 2, p16-21. 6p. |
| Databáze: | Academic Search Ultimate |
| Externí odkaz: |
|